Dupont Pharmaceuticals Company

Bristol-myers Squibb Pharma Company

The Dupont Merck Pharmaceutical Company

Michael B Maurin

Jaan A Pesti

Jianguo Yin

Surendra M Bahal

Philip Ma

Joseph M Fortunak

James R Moore

Lilian Alicia Radesca

Lucius Thomas Rossano

Shelley R Rabel

Goss S Kauffman

George F Huhn

David John Meloni

Lin Hua Zhang

Randall K Ward

Kenneth S Field

The potent reverse transcriptase inhibitor Efavirenz is produced in crystalline form. Crystalline Efavirenz exists in several physical forms which are-designated Forms 1, 2, 3 and 4, and are characterized by x-ray powder diffraction and differential scanning calorimetry. Pharmaceutical compositions and methods are useful for the treatment of the human immunodeficiency virus (HIV).

Crystalline Efavirenz

The potent platelet glycoprotein IIb/IIIa antagonist, roxifiban, is produced in crystalline form. Crystalline roxifiban exists in two polymorphic forms, designated Form 1 and Form 2. These polymorphic forms are characterized by x-ray powder diffraction and solid-state carbon NMR. Pharmaceutical compositions and methods for the treatment or prevention of diseases mediated by platelet aggregation are described.

Crystalline roxifiban

A palatable oral liquid pharmaceutical composition of benzoxazinone compounds useful as HIV reverse transcriptase inhibitors comprising the benzoxazinone active ingredient in a liquid vehicle comprising medium chain fatty acid triglycerides. Other formulating agents such as sweetening agents, lecithin suspending agents, etc. may be optionally added.

Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors

The present invention relates to processes for the synthesis of a crystalline polymorph of 10,10-Bis((2-fluoro-4-pyridinyl)methyl)-9(10H)-Anthracenone in high purity. The product is useful in the synthesis of pharmaceutical compounds for the reduction of cholinergic system dysfunction.

Crystalline 10,10-Bis((2-fluoro-4-pyridinyl)methyl)-9(10H)-Anthracenone and an improved process for preparing the same

Physically and chemically stable pharmaceutical compositions useful for administering etanidazole by injection are described. These compositions are essentially aqueous solutions having a pH less than or equal to 5.5, and containing etanidazole, a buffer system, and a tonicity-adjusting agent, and they are optionally stabilized by the addition of a stabilizing agent or by autoclaving.

Etanidazole injectable solution

Growing community of inventors

Wilmington, DE, United States of America

Michael B Maurin